Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro
- PMID: 3349462
Antiinvasive activity of estramustine on malignant MO4 mouse cells and on DU-145 human prostate carcinoma cells in vitro
Abstract
Estramustine (EM) is a conjugate of estradiol and nor-nitrogen mustard (nor-HN2), which is effective in the treatment of prostate cancer. We have compared the effect of EM with that of the known microtubule inhibitor vinblastine (VLB) on the following functions of malignant MO4 mouse cells and of DU-145 human prostate cancer cells in vitro: directional migration, invasion; and the organization and the assembly/disassembly equilibrium of microtubule complexes. The circular area covered by cells migrating from an aggregate explanted on a solid substrate was taken as an index of directional migration. Invasion was studied through confrontation of MO4 or DU-145 cells with fragments of embryonic chick heart in organ culture. Microtubules were investigated immunocytochemically and through immunodetection on protein blots. VLB and EM inhibited directional migration and invasion of MO4 and DU-145 cells in a dose-dependent manner; equimolar combinations of estradiol plus nor-nitrogen mustard did not mimic these effects. At anti-invasive concentrations VLB led to partial disassembly of microtubule complexes, whereas EM resulted in an abnormal pattern of microtubule complexes without alteration of the overall assembly/disassembly equilibrium. Combined treatment with VLB and EM resulted in an enhanced VLB effect, namely complete disassembly. In all tests DU-145 cells were more sensitive to both VLB and EM than were MO4 cells, and the effects were less reversible. The present experiments showed that EM shares an anti-invasive activity with other microtubule inhibitors.
Similar articles
-
Immunofluorescent studies of the anti-microtubule effects of the anti-cancer drug estramustine.Anticancer Res. 1987 Nov-Dec;7(6):1165-71. Anticancer Res. 1987. PMID: 3327449
-
Antiinvasive effect of racemic 1-O-octadecyl-2-O-methylglycero-3-phosphocholine on MO4 mouse fibrosarcoma cells in vitro.Cancer Res. 1985 Jan;45(1):351-7. Cancer Res. 1985. PMID: 4038380
-
Growth of prostatic cancer cells, DU 145, as multicellular spheroids and effects of estramustine.Anticancer Res. 1993 Sep-Oct;13(5A):1261-8. Anticancer Res. 1993. PMID: 8239495
-
Intracellular effects of estramustine (Estracyt/Emcyt).Prog Clin Biol Res. 1989;303:169-75. Prog Clin Biol Res. 1989. PMID: 2674983 Review. No abstract available.
-
Estramustine-based chemotherapy.Semin Urol Oncol. 1997 Feb;15(1):13-9. Semin Urol Oncol. 1997. PMID: 9050135 Review.
Cited by
-
Randomized Phase II trial assessing estramustine and vinblastine combination chemotherapy vs estramustine alone in patients with progressive hormone-escaped metastatic prostate cancer.Br J Cancer. 2004 Jan 12;90(1):100-5. doi: 10.1038/sj.bjc.6601468. Br J Cancer. 2004. PMID: 14710214 Free PMC article. Clinical Trial.
-
Tryprostatin A, a specific and novel inhibitor of microtubule assembly.Biochem J. 1998 Aug 1;333 ( Pt 3)(Pt 3):543-8. doi: 10.1042/bj3330543. Biochem J. 1998. PMID: 9677311 Free PMC article.
-
Stabilization of microtubule dynamics by estramustine by binding to a novel site in tubulin: a possible mechanistic basis for its antitumor action.Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10560-4. doi: 10.1073/pnas.94.20.10560. Proc Natl Acad Sci U S A. 1997. PMID: 9380674 Free PMC article.
-
Resistance to the antimitotic drug estramustine is distinct from the multidrug resistant phenotype.Br J Cancer. 1991 Aug;64(2):267-73. doi: 10.1038/bjc.1991.290. Br J Cancer. 1991. PMID: 1892755 Free PMC article.
-
Estramustine phosphate sodium. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in prostate cancer.Drugs Aging. 1995 Jul;7(1):49-74. doi: 10.2165/00002512-199507010-00006. Drugs Aging. 1995. PMID: 7579781 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical